REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a live webcast on May 14, 2026 at 8:00 a.m. ET to discuss topline results from the pivotal trial of RGX-202, its next-generation investigational gene therapy for Duchenne muscular dystrophy.

The company will also report first quarter 2026 financial results and operational highlights pre-market on May 14. The live webcast and an archived replay (available for ~30 days) are accessible via the investor section at regenxbio.com.

Positive

• Topline pivotal trial results for RGX-202 scheduled May 14, 2026
• First quarter 2026 financial results to be released pre-market May 14, 2026
• Webcast will feature three leading Duchenne physicians as presenters

Negative

• None.

News Market Reaction – RGNX

+10.85%

3 alerts

+10.85% Session close to close

-7.1% Trough Tracked

$527.53M Market Cap

0.0x Rel. Volume

In the May 6 session, RGNX gained 10.85%, reflecting a significant positive market reaction. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.8% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +10.8% in the session following this news. A strong positive reaction aligns with the importance of RGX‑202 as a pivotal neuromuscular asset, especially given prior clinical updates often saw shares fall despite good data (4 of 5 past clinical headlines were negative movers, average -5.4%). Investors may have reassessed risk around Duchenne outcomes and funding flexibility, supported by a $300,000,000 shelf capacity. Sustainability would depend on future trial details and execution against upcoming regulatory milestones.

Key Figures

Webcast date: May 14, 2026 Webcast time: 8:00 a.m. ET Quarter reported: Q1 2026 +2 more

5 metrics

Webcast date May 14, 2026 RGX-202 pivotal topline results discussion

Webcast time 8:00 a.m. ET Scheduled RGX-202 topline webcast start time

Quarter reported Q1 2026 Financial results to be reported with webcast

Quarter end date March 31, 2026 Period covered by upcoming Q1 2026 results

Replay availability ≈30 days Archived webcast replay duration

Previous Clinical trial Reports

5 past events · Latest: Mar 11 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 11	Duchenne interim data	Positive	-5.3%	Positive AFFINITY DUCHENNE Phase I/II interim data for RGX-202 pivotal dose cohort.
Sep 05	MPS II pivotal data	Positive	+3.1%	Positive 12‑month pivotal CAMPSIITE data for RGX-121 in MPS II patients.
Jul 10	RGX-202 preclinical	Positive	-1.2%	Preclinical results showing functional benefits of RGX-202 microdystrophin construct.
Jun 05	Duchenne functional data	Positive	-17.1%	AFFINITY DUCHENNE functional gains and high microdystrophin expression at dose level 2.
Oct 21	Wet AMD data	Positive	-6.6%	Positive Phase II fellow-eye data for ABBV-RGX-314 in bilateral wet AMD.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates have mostly been positive but were often followed by negative share reactions.

Recent Company History

Over the past year, REGENXBIO has repeatedly reported positive clinical data across RGX-202, RGX-121 and ABBV‑RGX‑314. Updates included functional gains in Duchenne patients, strong biomarker reductions in MPS II, and meaningful treatment-burden reductions in wet AMD, yet four of five clinical‑trial news days saw the stock trade down. Today’s announcement of an upcoming RGX‑202 pivotal topline webcast and Q1 2026 results continues this clinical‑data narrative as the program moves toward potential regulatory milestones.

Key Terms

pivotal trial, gene therapy, Duchenne muscular dystrophy, webcast

4 terms

pivotal trial medical

"to discuss topline results from the pivotal trial of RGX-202"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

gene therapy medical

"next-generation investigational gene therapy for the treatment of Duchenne"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

Duchenne muscular dystrophy medical

"gene therapy for the treatment of Duchenne muscular dystrophy."

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

webcast technical

"it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Company will also report first quarter 2026 financial results and operational highlights --

ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET to discuss topline results from the pivotal trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy.

The webcast will feature leading Duchenne physicians including Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital, Carolina Tesi-Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health, and Diana Castro, M.D., Board Certified Neurologist and Neuromuscular Physician, Founder and Director Neurology and Neuromuscular Care Center and Founder and Director Neurology Rare Disease Center.

The company will also report financial results and operational highlights for the first quarter ended March 31, 2026 pre-market Thursday, May 14.

The live webcast can be accessed here and in the Investor section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-on-may-14-to-discuss-topline-results-from-pivotal-trial-of-rgx-202-for-duchenne-muscular-dystrophy-302763647.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present topline RGX-202 results and how can I watch?

The webcast will occur on May 14, 2026 at 8:00 a.m. ET. According to the company, the live webcast is available on regenxbio.com and an archived replay will be posted for approximately 30 days.

Will REGENXBIO (RGNX) report financial results on the same day as the RGX-202 topline update?

Yes. According to the company, REGENXBIO will report first quarter 2026 financial results and operational highlights pre-market on May 14, 2026, the same day as the RGX-202 topline webcast.

Who will present clinical context during REGENXBIO's (RGNX) May 14 webcast on RGX-202?

The webcast will feature leading Duchenne physicians, including Aravindhan Veerapandiyan, Carolina Tesi-Rocha, and Diana Castro. According to the company, these clinicians will discuss the pivotal RGX-202 topline results and clinical implications.

How long will the replay of REGENXBIO's (RGNX) RGX-202 webcast remain available?

According to the company, an archived replay of the webcast will be available for approximately 30 days following the presentation, accessible via the investor section on regenxbio.com.

What is RGX-202 in REGENXBIO's (RGNX) pipeline and why is the May 14 event important?

RGX-202 is described as a next-generation investigational gene therapy for Duchenne muscular dystrophy. According to the company, May 14 will present topline pivotal-trial results that could inform clinical and regulatory next steps.